DSDaniel Alejandro Silva Soto

Daniel Alejandro Silva Soto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Alejandro Silva Soto has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Paul David Morris

    Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield , Beech Hill Road, Sheffield S10 2RX

    3 shared publications
  • Angela Lungu

    Technical University of Cluj-Napoca

    2 shared publications
  • D. Rodney Hose

    Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom; Insigneo Institute for In Silico Medicine, Sheffield, United Kingdom; Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

    2 shared publications
  • Julian P. Gunn

    Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom; Department of Cardiology, Sheffield Teaching Hospitals, National Health Service Foundation Trust, Northern General Hospital, Sheffield, United Kingdom; Insigneo Institute for In Silico Medicine, Sheffield, United Kingdom

    2 shared publications
  • Patricia V. Lawford

    Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom; Insigneo Institute for In Silico Medicine, Sheffield, United Kingdom

    2 shared publications
  • Andrew James Narracott

    University of Sheffield

    1 shared publication

Latest Publications

  • Open Access

    Virtual Coronary Intervention

    by Rebecca C. Gosling, Paul D. Morris, Daniel A. Silva Soto, Patricia V. Lawford, D. Rodney Hose, Julian P. Gunn


  • Open Access

    Fast Virtual Fractional Flow Reserve Based Upon Steady-State Computational Fluid Dynamics Analysis

    by Paul D. Morris, Daniel Alejandro Silva Soto, Jeroen F.A. Feher, Dan Rafiroiu, Angela Lungu, Susheel Varma, Patricia V. Lawford, D. Rodney Hose, Julian P. Gunn


  • Top Cited Papers
    Open Access

    Computational fluid dynamics modelling in cardiovascular medicine

    by Paul D Morris, Andrew Narracott, Hendrik von Tengg-Kobligk, Daniel Alejandro Silva Soto, Sarah Hsiao, Angela Lungu, Paul Evans, Neil W Bressloff, Patricia V Lawford, D Rodney Hose, et al.

    This paper reviews the methods, benefits and challenges associated with the adoption and translation of computational fluid dynamics (CFD) modelling within cardiovascular medicine. CFD, a specialist area of mathematics and a branch of fluid mechanics, is used routinely in a diverse range of safety-critical engineering systems, which increasingly is being applied to the cardiovascular system. By facilitating rapid, economical, low-risk prototyping, CFD modelling has already revolutionised research and development of devices such as stents, valve prostheses, and ventricular assist devices. Combined with cardiovascular imaging, CFD simulation enables detailed characterisation of complex physiological pressure and flow fields and the computation of metrics which cannot be directly measured, for example, wall shear stress. CFD models are now being translated into clinical tools for physicians to use across the spectrum of coronary, valvular, congenital, myocardial and peripheral vascular diseases. CFD modelling is apposite for minimally-invasive patient assessment. Patient-specific (incorporating data unique to the individual) and multi-scale (combining models of different length- and time-scales) modelling enables individualised risk prediction and virtual treatment planning. This represents a significant departure from traditional dependence upon registry-based, population-averaged data. Model integration is progressively moving towards ‘digital patient’ or ‘virtual physiological human’ representations. When combined with population-scale numerical models, these models have the potential to reduce the cost, time and risk associated with clinical trials. The adoption of CFD modelling signals a new era in cardiovascular medicine. While potentially highly beneficial, a number of academic and commercial groups are addressing the associated methodological, regulatory, education- and service-related challenges.